Federal Register #2026-12070

NCI Offers Nonexclusive Licensing of A1847 Human Ovarian Carcinoma Cell Line for Research

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking nonexclusive licensees for the A1847 human ovarian carcinoma cell line, a government-owned research tool. - Government Buyer: - Department of Health and Human Services - National Institutes of Health (NIH) - National Cancer Institute (NCI) - OEM Highlight: - National Cancer Institute (NCI) is the sole OEM and provider of the cell line - Product/Service Requested: - A1847 Human Ovarian Carcinoma Cell Line (NIH Reference Number: E13720230) - No specific purchase quantities; opportunity is for licensing, not direct procurement - Cell line is BRCA1-deficient, tumorigenic, and derived from a metastatic ovarian cancer patient - Characterized by isozyme phenotype, STR analysis, and karyotyping - Unique/Notable Requirements: - Intended for research use in studying ovarian cancer mechanisms, drug resistance, and therapeutic development - Suitable for preclinical proof-of-concept studies and mechanistic oncology research - Opportunity is for nonexclusive licensing of a well-characterized, government-owned biological material

Description

The National Cancer Institute (NCI) is seeking licensees for a tumorigenic cell line, A1847, derived from a patient with metastatic ovarian cancer. This BRCA1 deficient cell line serves as a model for researchers studying cell cycle regulation, tumor suppression, and drugs that aid in DNA damage repair. The cell line is well-characterized and can be used to identify therapeutic targets and screen drug candidates against ovarian cancer. NCI is offering nonexclusive licenses for this research material to support commercial and research development.

View original listing